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Abstract. Sequential monotherapy is the most widely used therapeutic approach in the treatment
of HBV chronic infection. Unfortunately, under therapy, in some patients the hepatitis virus mutates
and gives rise to variants which are drug resistant. We wonder whether those patients would have
benefited from the choice of combination therapy instead of sequential monotherapy. To study
the action of these two therapeutic approaches and to explain the emergence of drug resistance,
we propose a stochastic model for the infection within a patient who is treated with two drugs,
either sequentially or contemporaneously, and who, under the first kind of therapy develops a
strain of the virus which is resistant to both drugs. Our stochastic model has a deterministic
approximation which is a slight modification of a classic 3-strain model. We discuss why stochastic
simulations are more suitable than the study of the deterministic approximation, when modelling
the rise of mutations (this is mainly due to the amplitude of the stochastic fluctuations). We
run stochastic simulations with suitable parameters and compare the time when, under the two
therapeutic approaches, the resistant strain first reaches detectability in the serum viral load. Our
results show that the best choice is to start an early combination therapy, which allows to stay drug
resistance free for a longer time and in many cases leads to viral eradication.
Keywords: viral dynamics stochastic modelling, deterministic approximation, ordinary differential
equations model, mutation, drug resistance.
1. Introduction
Hepatitis B virus is the cause of one of the most common infections in the world. Its consequences,
such as the liver cirrhosis and the hepatocellular carcinoma, affecting approximately 25% of patients
with chronic HBV infection, are important causes of morbidity and mortality worldwide [1, 27, 31,
35]. Antiviral therapy has demonstrated to have an important role in reducing both the markers
of liver disease progression and, above all, the evolution to cirrhosis and hepatocellular carcinoma
[35]. It has been shown that high serum levels of HBV-DNA (> 104 copies/ml) are predictive of an
increased risk of hepatocellular carcinoma, regardless of the transaminase level and the presence of
liver cirrhosis [11]: therefore it is clear that the chronic patient with high viral loads needs to be
treated with antiviral therapy (which should be considered a preventive and anti-cancer therapy
[35]).
So far antiviral drugs are mainly used in a sequential monotherapy (that is, only one drug
is employed at a time and if an increase in viral load is observed, then the drug is substituted
with another one). Some unsolved problems remain today: viral eradication (certified by the
disappearance of HBsAg or cccDNA), which would allow the discontinuation of the therapy, is
obtained in only 10% of treated patients [28]. On the other hand, the long term treatment with
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sequential monotherapy [10, 21, 52], is likely to select drug-resistant strains, because of the onset of
viral breakthrough and mutant escape (that is the emergence of variant viruses) under the selective
pressure of medications [24, 46].
As stated in the international guidelines, the combination therapy (that is, therapy with a cocktail
of drugs) has a well-defined role in the treatment of chronic hepatitis B, in selected categories of
patients, such as those with decompensated cirrhosis, HIV co-infection, pre-existing mutations and
post-liver transplantation [10, 21, 52, 57]. To date, only a few studies have attempted to compare the
effectiveness of the two different approaches (combination versus monotherapy) in treatment-naive
patients. These studies did show promising results in favor of combination therapy ([22, 43, 59, 60]).
We conjecture that combination therapy, as a therapy for chronic HBV infection, is preferable
to sequential monotherapy. Our conjecture is based on the following observation: both in in
vitro and in vivo studies, the antiviral drugs for treatment of hepatitis B have shown a non-
competitive but rather additive and potentially synergistic mechanism of action ([15, 17, 43, 47, 64]).
These observations reveal potential advantages of combination therapy, in terms of strength of
antiviral effects and diminished or delayed resistance. Moreover, despite being a stable DNA virus,
hepatitis B virus replicates in the host cell through a RNA phase [39], which makes it similar to the
Human Immunodeficiency Virus (HIV). The natural history of HIV infection has been radically
transformed by the introduction of combination antiviral therapy (Highly Active Antiretroviral
Therapy, HAART) [9]. Therefore we believe that this kind of therapy should be beneficial also for
HBV treatment. In particular we infer that under combination therapy the appearance of drug
resistance is less likely, or at least, occurs after a longer time.
The behaviour of drug-resistant strains is a priori unpredictable. Therefore, we believe that it is
important to use a mathematical model, which takes into account the emergence of mutants of the
virus. The usual pattern of viral load under treatment, that has been captured by mathematical
models introduced for instance in [45] and [58], is a rapidly decaying phase followed by a slower
decaying phase (see for instance [58, Figure 1, Figure 2]). The standard mathematical model for
viral dynamics within a single patient is given by a three ordinary differential equations system (in
short, ODEs system): 
T˙ = λ− δ′T − αV T ;
Y˙ = αV T − δY ;
V˙ = pY − cV ;
(1.1)
where T denotes target (uninfected) hepatocytes which are produced at rate λ, die at rate δ′T and
are infected at a rate αV T ; Y denotes infected hepatocytes which die at rate δY (δ possibly larger
than δ′) and V denotes free virus. Virions are produced from infected cells at rate pY and are
cleared from bloodstream at rate cV . The system has no exact solutions but approximate solutions
may be obtained under different hypotheses.
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If the patient undergoes treatment, the drug acts against reproduction and/or infection. In the
model this is explained by introducing the efficacy parameters ε ∈ [0, 1] ([45, 58]) and η ∈ [0, 1]
([33, 40]). In (1.1) one must replace α by (1 − η)α and p by (1 − ε)p. The parameters ε and η
respectively indicate the ability of treatment to block viral production or infection (the extremal
values 0 and 1 refer to no ability at all and complete ability, respectively). Of course the behaviour
under no treatment is retrieved setting η = ε = 0. This model has been used in several papers
(for chronic HBV infection, HIV infection or acute HBV infection) to fit experimental data under
treatment with different drugs, leading to estimates for some of the parameters involved, mainly
for ε, c and δ ([13, 14, 29, 33, 40, 44, 58, 62, 63]).
Unfortunately, in a certain fraction of patients, after an initial decrease, the serum viral load
starts increasing and one may eventually face secondary therapeutic failure, which is conventionally
defined as a rebound of at least 1 log 10 in viral load above the lowest level previously reached. This
failure is due to the emergence of drug-resistant strains (which are usually not observed without
therapy). In the literature one can find several attempts to model drug resistance: in [37] and
[61] there are two HIV strains infecting CD4+ cells (one susceptible and one resistant to therapy).
In [49] and [50] the standard model (1.1) is mimicked: there are separate equations for the free
susceptible virus and the free resistant one; also infected cells are considered separately when
infected with the resistant or with the susceptible strain. Each of these models is deterministic: a
fixed fraction of the reproductions of the susceptible virus leads to mutation (reverse mutations,
from the resistant strain to the susceptible one, are considered as negigible). Nevertheless the
true nature of the interactions between target cells, infected cells, free virus and immune system
is stochastic. It is well-known that the use of deterministic models instead of stochastic ones is
justified by the large number of interacting particles. We recall in Section 2 the theorems which
are the basis of this approximation. It has already been observed (see [48]) that in reality even if a
particular strain is generated by mutation, there is some probability that it will disappear due to
stochasticity. Moreover, often frequencies of mutants are very small and stochastic fluctuations are
far from being negligible (see Theorem 2.4 and the comments thereafter). We therefore develop a
stochastic 3-strain model (Section 2) to which we devote our study.
The idea is that the mutations are pre-adaptive, linked to random errors of the replicative
process. Hence, the antiviral therapy does not determine any resistant strains, but simply selects
them [36, 39, 42, 46, 48, 49, 50]. Our main question is whether patients who during sequential
monotherapy develop drug resistance, leading to secondary treatment failure, would have benefited
from the choice of combination therapy instead (that is, drug resistance would not have appeared,
or at least it would have at a later time). Thus we model the situation where the physician has two
drugs at hand: drug A and drug B, drug A being the one which is known to be the more efficient.
Note that this is the simplest case where the dilemma between sequential and combination therapy
arises (two being the minimum number of drugs possible in combination therapy).
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We suppose that the patient is treatment-naive and has a high serum viral load of HBV virions,
of a type (usually the wild-type) that we call type 1. By hypothesis, if cured with drug A, the
patient will develop a resistant strain, type 2 virus, whose serum viral load will increase. Let us
stress here that by definition strain 2 of the virus is the one that first emerges during therapy, as
resistant to drug A. Its genotype is a priori unknown. Therapy with drug B will prove effective in
striking type 2 down, but eventually another mutation will arise (type 3 mutants, again a priori
of unknown genotype). Our main question is whether providing drug A and drug B together can
significantly delay the instant when, the concentration of the variant 3 in serum exceeds the limit
of detection (that is, with current tests at hand, approximately 20 copies/ml). If so, that would be
an argument in favour of combination therapy.
Here is the outline of the paper. In Section 2 we recall the mathematical results which allow us to
approximate the average behaviour of stochastic models with deterministic models. We introduce
our stochastic model (Definition 2.1) and discuss why, when mutants viral loads are low, the
description by means of the stochastic model is more accurate than the one with the deterministic
model.
In Section 3 we analyze the equilibrium points of the ODEs system (2.3), which is the determinis-
tic approximation of our stochastic model (the system has no exact solutions). The stability of the
equilibria, depending on the reproductive ratios of the three types, is discussed (see Table 1). The
emergence under therapy of drug-resistant strains which are not otherwise observed is explained
assuming that when present together with the wild type, the viral loads of type 2 and type 3 are
small (in absolute value or at least if compared to the viral load of type 1).
In Section 4 we first discuss how we can derive the unknown parameters of the infection. The idea
is to make some assumptions on the equilibrium viral loads of the 3 strains and to associate to any
plausible set of viral loads a corresponding parameter set. This leads to 46 different parameter sets
which are tested with stochastic simulations, under sequential or combination therapy. Different
initial conditions are considered (see Tables 4, 4, 4).
Section 5 is devoted to the discussion of the consequences of our results onto the choice of the best
therapeutic approach in the cure of chronic HBV infection. In particular our results suggest that
combination therapy is the best choice if started at the early stages of the chronic HBV infection.
2. Stochastic model and deterministic approximation
The simplest stochastic model for viral reproduction is the branching process ([23]). This model
is very rough (the behaviour of the average number of particles is either exponential growth,
stationarity or exponential decrease), therefore to add complexity, one introduces space and/or
interaction between particles, see [18]. Adding space one obtains the branching random walk
where the reproductive capacity of the virus depends on its “location” (which may represent not
only position but also type): its behaviour on complex networks has been studied for instance in
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[5, 6, 65]. In order to obtain a more realistic behaviour, where only a certain maximal viral load
can be achieved (or at least, growth slows down when the viral population is too large), we can put
interaction into play (logistic competition is perhaps the simplest interaction). Spatially displaced
interacting particle systems have been studied for instance in [2, 3, 4].
The model that we introduce here is not spatial, and is essentially a modification of the stochastic
model which lies underneath (1.1). We first reduce to two the number of unknowns in (1.1). Indeed
we assume that, by homeostasis, the total number of hepatocytes is constant, that is T + Y = H0,
where H0 is fixed. Namely we suppose that, whenever an infected hepatocyte dies, it is replaced
(almost immediately) by an uninfected one. This means that infected hepatocytes are not destroyed
by the immune system at a too fast rate. This is in agreement with the common belief that cytotoxic
T lymphocytes may directly inhibit viral replication and thus inactivate HBV without killing the
infected hepatocyte, and that in chronically infected patients, infected hepatocytes escape immune
recognition, sparing massive liver damage (see [12, 19, 32]). This is particularly true during the first
stage of the disease, the compensated phase (which lasts years under a correct antiviral therapy)
or in the large group of HBV infected people called inactive carriers [53]. This assumption allows
us to deal only with the dynamics of Y and V and to replace T with H0 − Y . Now we partition
V into the three types of virions V1, V2, V3 and Y into Y1, Y2 and Y3 (according to the type of
infection).
The process is characterized by the following positive parameters:
(a) the infection parameters α1, α2, α3, where αi corresponds to the rate at which virions of type
i infect target hepatocytes (i = 1, 2, 3);
(b) the production parameters p1, q2, r3, i.e. the rates at which hepatocytes which are infected
with type 1, type 2 and type 3 virus respectively, produce virions of the same type;
(c) the mutation parameters p2 and q3, i.e. the rates at which hepatocytes which are infected with
type 1 and type 2 virus respectively, produce virions of type 2 and type 3;
(d) the hepatocytes clearance rates δ1, δ2, δ3, where δi corresponds to the rate at which hepatocytes
carrying type i infection are removed and thus replaced by target hepatocytes (i = 1, 2, 3);
(e) the free virions clearance rates c1, c2, c3, where ci corresponds to the rate at which virions of
type i are cleared from bloodstream (i = 1, 2, 3).
Definition 2.1 (Stochastic model). Given the positive parameters αi, δi, ci (i = 1, 2, 3) and p1,
q2, r3, p2, q3, the stochastic process (Y1(t), Y2(t), Y3(t), V1(t), V2(t), V3(t))t≥0 is a continuous time
Markov chain with values in N6. The transition rates qk,k+l (k ∈ N6, l ∈ Z6) are as follows, for all
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k 6= 0, 
αi
(
1− Y1H0 − Y2H0 − Y3H0
)
Vi if l = ei, i = 1, 2, 3;
δiYi if l = −ei, i = 1, 2, 3;
p1Y1 if l = e4;
p2Y1 + q2Y2 if l = e5;
q3Y2 + r3Y3 if l = e6;
ciVi if i = 1, 2, 3 and l = −e4,−e5,−e6, respectively;
0 otherwise;
(ei being the elements of the natural base of R6).
Although this is a random process, results by Kurtz prove that its dynamic behaviour is approx-
imated by the solution of an ODEs system ([25], [26], see also [51] for an example of application in
epidemic models). These results apply to density dependent processes, hence we must consider a
modification of our process.
Definition 2.2 (Density dependent process and density process). A one-parameter family of con-
tinuous time Markov chains (X(N)(t))t≥0 with state space E ⊆ Zd and transition rates (q(N)ij ) is
called density dependent if there exists a continuous function f : Rd × Zd → R, such that
q
(N)
k,k+l = Nf
(
k
N
, l
)
, l 6= 0 and k, l ∈ Zd.
Suppose (X(N)(t))t≥0 is a density dependent process. By rescaling with N we get the density process
(XN (t))t≥0 := ( 1NX
(N)(t))t≥0.
Under certain conditions (XN (t))t≥0 converges to a deterministic process that is the solution of
a system of first order ODEs that is governed by the following function F :
F (x) =
∑
l∈Zd
lf(x, l),
as stated in [25, Theorem 3.1] (a slightly different version of the statement, claiming almost sure
convergence, can be found in [20, Theorem 2.1, p.456]). We recall the theorem here.
Theorem 2.3 (Deterministic Approximation). Suppose that there exists an open set E ⊆ Rd such
that the function F is Lipschitz continuous on E and
sup
x∈E
∑
l
|l|f(x, l) <∞; lim
r→∞ supx∈E
∑
|l|>r
|l|f(x, l) = 0.
Then, for every trajectory (x(s, x0), s ≥ 0) satisfying the following system of ODEs{
d
dsx(s, x0) = F (x(s, x0))
x(0, x0) = 0
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(where x(s, x0) ∈ E, 0 ≤ s ≤ t), limN→∞XN (0) = x0 implies that for every δ > 0,
lim
N→∞
P( sup
0≤s≤t
|XN (s)− x(s, x0)| > δ) = 0.
This theorem implies that the process (XN (t))t≥0 can be approximated to first order by a deter-
ministic process, for large N. If the density process (XN (t))t≥0 is initially close to x0, it will tend
to stay close to the trajectory (x(s, x0), s > t) in some appropriate time-interval. The behaviour of
the random fluctuations of the density process (XN (t))t≥0 around its deterministic approximation
is given by the following theorem ([20, Ch.11], see also [51]).
Theorem 2.4 (Fluctuations). If for all compact set K ⊂ E we have ∑l |l|2 supx∈K f(x, l) < ∞
and f(·, l) and ∂F are continuous, then the process {√N(XN (s) − x(s, x0))}s≥0 converges in law
to a fixed process V .
This result implies that order of magnitude of the stochastic fluctuations of XN around its
deterministic approximation x, is 1/
√
N .
In our case, taking xi = Yi/N , i = 1, 2, 3, xi = Vi−3, i = 4, 5, 6, N = H0, we have
f(x, l) =

αi (1− x1 − x2 − x3)xi+3 if l = ei, i = 1, 2, 3;
δixi if l = −ei, i = 1, 2, 3;
p1x1 if l = e4;
p2x1 + q2x2 if l = e5;
q3x2 + r3x3 if l = e6;
cixi if l = −ei, i = 4, 5, 6;
0 otherwise.
Thus F has the following expression and it is easily checked that the hypotheses of Theorem 2.3
are satisfied:
F (y1, y2, y3, v1, v2, v3) =

α1 (1− y1 − y2 − y3) v1 − δ1y1
α2 (1− y1 − y2 − y3) v2 − δ2y2
α3 (1− y1 − y2 − y3) v3 − δ3y3
p1y1 − c1v1
p2y1 + q2y2 − c2v2
q3y2 + r3y3 − c3v3
 . (2.2)
An estimate for H0 is 2 · 1011 ([54], also in accordance with the result of 139·106 cells/g in [55] and
an average weight for a human liver of 1.5·103g). Thus we may infer that, in a time interval of at
least 30-40 years, the trajectories of the solution of the following system of ODEs
(y˙1, y˙2, y˙3, v˙1, v˙2, v˙3)
T = F (y1, y2, y3, v1, v2, v3). (2.3)
approximate the trajectories of the stochastic process
(
Y1(t)
H0
, Y2(t)H0 ,
Y3(t)
H0
, V1(t)H0 ,
V2(t)
H0
, V3(t)H0
)
t≥0
. Nev-
ertheless, by Theorem 2.4, the fluctuations are of order 1/
√
2 · 1011 ≈ 2.2 · 10−6. Thus when a
fraction of infected hepatocytes or Vi(t)/H0 is smaller than 10
−6 then the approximation is far
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from being accurate. This is particularly true at the early stages of the infection (all the Vis are
low) or when a mutation has just appeared (V2 and/or V3 are low).
Remark 2.5 (The model under therapy). The stochastic model we defined in (2.1) and its approx-
imation, that is the solution of (2.3) are not only models for the case where there is no therapy,
but also where there is therapy with drug A or B or both. We only have to change the parameters
involved by therapy. To be precise, we denote by εA, ηA the efficacies parameters of drug A against
strain 1, by εB1, ηB1 and εB2, ηB2 the efficacies parameters of drug B against strain 1 and strain
2 respectively, and by εC , ηC the efficacy parameters of the combination of drug A and B against
strain 1.
If therapy with drug A only is in act, then we must replace α1, p1 and p2 by (1−ηA)α1, (1−εA)p1
and (1 − εA)p2 respectively; if we use drug B only then we replace α1, p1, p2, α2, q2 and q3 by
(1− ηB1)α1, (1− εB1)p1 (1− εB1)p2, (1− ηB2)α2, (1− εB2)q2 and (1− εB2)q3 respectively; in the
case of combination therapy, then α1, p1 and p2 must be replaced by (1 − ηC)α1, (1 − εC)p1 and
(1− εC)p2 respectively, while α2, q2 and q3 are modified as in the case of the cure with B only (by
hypothesis, drug A has no impact on the type 2 infection).
3. Analysis of the deterministic model
The ODEs system (2.3) has no exact solution, thus in order to understand its behaviour, we start
by analyzing its equilibria. Before going into the details of the analysis, we make some assumptions
on the parameters:
(1) The viral clearance parameters ci do not depend on the type, namely c := c1 = c2 = c3.
(2) p2  p1, q3  q2 and also p2 and q3 have small absolute values.
For the first assumption we note that the cis depend only on the lifetime of virions in bloodstream,
thus on the antibodies production of the infected patient. We assume that this production does
not depend on the variant (this may of course not be the case, but here we want to avoid a large
number of unknown parameters). In (2), p1+p2 and q2+q3 represent the reproduction rates of type
1 and type 2 infected hepatocytes respectively; p1 and q2 are the rates of conformal reproductions,
while p2 and q3 are the rates of non-conformal reproductions. Assumption (2) follows, since the
probability of mutation is very small.
An important role in the stability of the equilibria is played by the basic reproductive ratios of
the three variants
R1 =
α1p1
cδ1
, R2 =
α2q2
cδ2
, R3 =
α3r3
cδ3
. (3.4)
Note that if the patient is undergoing therapy the corresponding infection and production param-
eters have to be changed according to Remark 2.5. For instance, under therapy with drug A, the
basic reproductive ratio of the type 1 variant becomes (α1p1(1− ηA)(1− εA))/(cδ1).
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There are four equilibrium points, that is, solutions of F (x) = 0 (F taken from (2.2)): the
disease-free state and three infected equilibria X1 (with all variants present), X2 (where the first
variant is cleared) and X3 (with only the third mutant present). An equilibrium point x is locally
asymptotically stable if all the eigenvalues of JF (x) are negative, where JF (x) is the Jacobian
matrix of F .
JF (x) =

−(α1v1 + δ1) −α1v1 −α1v1 α1β 0 0
−α2v2 −(α2v2 + δ2) −α2v2 0 α2β 0
−α3v3 −α3v3 −(α3v3 + δ3) 0 0 α3β
p1 0 0 −c 0 0
p2 q2 0 0 −c 0
0 q3 r3 0 0 −c
 ,
where β = 1− y1 − y2 − y3.
3.1. Disease-free equilibrium. X0 = (0, 0, 0, 0, 0, 0). JF (X0) has six eigenvalues:
−δ1 − c±
√
4α1p1 + (δ1 − c)2
2
,
−δ2 − c±
√
4α2q2 + (δ2 − c)2
2
,
−δ3 − c±
√
4α3r3 + (δ3 − c)2
2
.
These eigenvalues are real and they are all negative (hence X0 is locally asymptotically stable) if
Ri < 1 for all i = 1, 2, 3. If at least one Ri is larger than 1, then there is at least one eigenvalue
which is positive and X0 is locally asymptotically unstable.
3.2. The infected equilibrium without type 1 and type 2. X3 = (0, 0, y3,3, 0, 0, v3,3). It has
biological meaning (that is, y3,3 and v3,3 are positive) if and only if R3 > 1, since
v3,3 =
R3 − 1
R3
r3
c
, y3,3 = 1− 1
R3
=
c
r3
R3v3,3.
JF (X1) has six eigenvalues:
−α3r3(c+ δ1)±
√
(α3r3(c− δ1))2 + 4α1α3cδ3p1r3
2α3r3
,
−α3r3(c+ δ2)±
√
(α3r3(c− δ2))2 + 4α2α3cδ3q2r3
2α3r3
,
−α3r3 − c2 ±
√
4c3δ3 + (α3r3 − c2)2
2c
.
Easy computations show that X3 is locally asymptotically stable if and only if R3 > 1, R3 > R1
and R3 > R2.
3.3. The infected equilibrium without type 1 infection. X2 = (0, y2,2, y3,2, 0, v2,2, v3,2). It
has biological meaning if and only if R2 > 1 and R2 > R3, since
v2,2 =
q2
c
(R2−1)(R2−R3)
R2(R2−R3+R3q3/r3) , v3,2 =
q3(R2−1)
c(R2−R3+R3q3/r3) =
q3
q2
R2
R2−R3 v2,2
y2,2 =
c
q2
v2,2, y3,2 =
c
r3
R3
R2
v3,2.
Two eigenvalues are
1
2
(
−c− δ1 ±
√
(δ1 − c)2 + 4α1p1(1− y2,2 − y3,2)
)
,
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which are negative if and only if R1 < 1/(1− y2,2 − y3,2) = R2. The other four eigenvalues are the
solutions of a quartic equation and have expressions which are too involved to be studied here. We
prefer to study the approximated solutions obtained substituting q3 ≈ 0 (and v3,2 ≈ 0, which is
plausible if R2 −R3 is not too small compared with R2 − 1) in the characteristic polynomial:
1
2
(
−α2v2,2 − δ2 − c±
√
(α2v2,2 + δ2 − c)2 + 4α2q2(1− y2,2 − y3,2)
)
1
2
(
−c− δ3 ±
√
(δ3 − c)2 + 4α3r3(1− y2,2 − y3,2)
)
.
Computations show that these approximate eigenvalues are all negative if and only if v2,2 > 0 and
R2 > R3 respectively. Thus X2 is locally asymptotically stable if and only if R2 > 1, R2 > R1
and R2 > R3.
3.4. The infected equilibrium with type 1. X1 = (y1,1, y2,1, y3,1, v1,1, v2,1, v3,1), where
v1,1 =
p1
c y1,1, v2,1 =
R1
R2
q2
c y2,1, v3,1 =
R1
R3
r3
c y3,1,
y2,1 =
R2
R1−R2
p2
q2
y1,1, y3,1 =
p2q3
q2r3
R2R3
(R1−R2)(R1−R3) .
(3.5)
As for y1,1, it has a complicated expression which is of no interest here (but can be obtained from
the relation y1,1 + y2,1 + y3,1 = 1− 1/R1). Here is its approximation if one substitutes q3 ≈ 0:
y1,1 ≈ (R1 − 1)(R1 −R2)
R1(R1 −R2 +R2(p2/q2)) .
Thus X1 has biological meaning if R1 > 1, R1 > R2 and R1 > R3. The eigenvalues of JF (X1) have
too complicated expressions, which make them untreatable. We study the approximate solutions
obtained with the substitutions q3 ≈ 0, p2 ≈ 0 (and v2,1 ≈ 0, which is plausible if p2 is small and
R1−1 is not too small compared with R1−R2) in the characteristic polynomial. The approximated
eigenvalues are
1
2
(
−α1v1,1 − δ1 − c±
√
(α1v1,1 + δ1 − c)2 + 4α1p1(1− y1,1 − y2,1 − y3,1)
)
,
1
2
(
−c− δ2 ±
√
(δ2 − c)2 + 4α2q2(1− y1,1 − y2,1 − y3,1)
)
,
1
2
(
−c− δ3 ±
√
(δ3 − c)2 + 4α3r3(1− y1,1 − y2,1 − y3,1)
)
.
Substituting y1,1 + y2,1 + y3,1 = 1− 1/R1, we get that X1 is locally asymptotically stable if R1 > 1,
R1 > R2 and R1 > R3 and unstable otherwise.
The conditions for stability can be summarized by Table 1.
3.5. Drug resistance explained by the model. Let us discuss how the presence of these equi-
libria and their stability can be biologically interpreted, and how this interpretation reflects onto
the parameters. We are modelling the infection within a chronic patient, therefore with no treat-
ment all three variants have reproductive ratios larger than 1. Moreover we believe that type 1 has
largest “fitness” and that type 2 has larger “fitness” than type 3, in the sense that variants are more
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R1 R2 R3 Equilibria
R1 < 1 R2 < 1 R3 < 1 X0 stable, other Xis unstable
R1 > 1 R2 < R1 R3 < R1 X1 stable, other Xis unstable
R1 < R2 R2 > 1 R3 < R2 X2 stable, other Xis unstable
R1 < R3 R2 < R3 R3 > 1 X3 stable, other Xis unstable
Table 1. Stability of the equilibria as a function of R1, R2, R3.
fit if, when present together at equilibrium, they have prevailing serum viral loads. We also define
the fittest variant to be the one with larger reproductive ratio (in a moment we will show that this
assumption leads to prevailing viral loads). Therefore in the beginning R1 > R2 > R3 > 1. With
no cure, after an appropriate amount of time, the system tends to lie in a neighbourhood of X1.
The effect of therapy is to lower the corresponding Ri, namely the new Ri becomes Ri(1−η)(1−ε),
where η and ε are the eficacy parameters of the drug acting against variant i. Thus, if the patient
is given drug A, then type 1 is cured and the system moves towards equilibrium X2, where variant
2 emerges and variant 1 disappears. If also type 2 is cured, with drug B (R2 is lowered), the new
equilibrium will be X3, that is, the patient will show drug resistance. The disease-free equilibrium
represents the desirable state where the patient is permanently cured, and can be reached, accord-
ing to the deterministic model, only if we have a drug at hand which acts also against the third
variant (by assumption, here X0 cannot be reached).
We believe that the reason why drug-resistant mutants are not observed unless under therapy
is the fact that, even if mutations do happen, nevertheless in the equilibrium together with the
wild type, mutants are numerically negligible. In other words, we assume that v2,1 and v3,1 are
negligible if compared to v1,1. From (3.5) we have
v2,1
v1,1
=
R1
R1 −R2 ·
p2
p1
;
v3,1
v1,1
=
R1R2
(R1 −R2)(R1 −R3) ·
p2q3
p1q2
,
whence the negligibility of the variants at X1 follows when p2 and q3 are small (with respect to p1
and q2 respectively) and R1 −R2 and R1 −R3 are not too small.
In the following figures we can see the behaviour of the viral loads of the three variants with
no therapy (Figure 2, converging towards X1), when curing only variant 1 (Figure 3, converging
towards X2) and with the combination therapy (Figure 4, converging towards X3). Note that the
scales are different for the three variants and that on the vertical axis we have the total number of
virions divided by H0.
The plots are obtained with MatLab R2013b, by numerical solutions of the differential equations
system with set of parameters: c = 0.65, δ1 = δ2 = δ3 = 0.0143, p1 = 2.6, p2 = 8.0997 · 10−10,
q2 = 0.2889, q3 = 10
−7, r3 = 0.26, α1 = 4.7668 · 10−3, α2 = 4.29 · 10−2, α3 = 4.7666 · 10−2 (this is
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one of the sets obtained as plausible in Section 4) and initial condition v1(0) = 0.8, v2(0) = 10
−7,
v3(0) = 10
−9, y1(0) = 0.25, y2(0) = v2(0) · cR2q2R1 , y3(0) = v3(0) · cR3r3R1 . The values for v1(0) and y1(0)
are taken from the literature on untreated chronic patients, v2(0) and v3(0) are arbitrarily chosen
(smaller than v2,1 and v3,1 respectively), yi(0) is taken multiplying vi(0) by yi,1/vi,1, i = 2, 3. This
means that we believe that the ratio of infected hepatocytes to viral load is the same before reaching
equilibrium and at equilibrium (this hypothesis was confirmed by the stochastic simulations run in
Section 4).
Figure 1. Viral loads of the three types with no therapy.
Figure 2. Viral loads of the three types curing only type 1.
Figure 3. Viral loads of the three types with therapy against types 1 and 2.
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4. Numerical comparison under sequential or combination therapy
4.1. Parameters and initial conditions. In order to understand the behaviour of the viral loads
of the three variants of the virus, with or without therapy, we need to perform numerical simula-
tions of the stochastic model (we used MatLab R2013b). We stress that we believe that the true
nature of the problem is stochastic. The deterministic approximation, which is traditionally em-
ployed, may not be accurate for low viral loads, due to the amplitude of the stochastic fluctuations
(Theorem 2.4). Moreover, according to the deterministic model, it suffices that some virions of type
3 (which has reproductive ratio larger than 1) are produced by mutation, and the infection cannot
be stopped unless one finds a cure against these mutants. In reality, by stochasticity, sometimes
mutants are produced but then also wiped out. We therefore devote our study mainly to stochastic
simulations.
We need to know the numerical values of the parameters involved, and of the initial condition.
The twelve parameters are: the infection parameters α1, α2 and α3; the clearance parameters c,
δ1, δ2 and δ3; the production parameters p1, p2, q2, q3, r3.
From [58] we have c = 0.65/day and δ1 = 0.0143/day. We assume that the clearance parameter
of the infected hepatocytes does not depend on the type of virus which infected the cell, that
is δ1 = δ2 = δ3 = 0.0143/day. The production parameter p1 can be obtained from the relation
p1 = cv1,1/y1,1 (see (3.5)). The values of v1,1 and y1,1 differ in different patients, we take average
values in chronic patients. The order of magnitude of the initial viral load in the patients of [58]
ranged from 107 to 109 copies/ml: for simplicity’s sake, we take a viral load v˜1,1 = 0.67 · 108
copies/ml. Note that this corresponds to v1,1 = 1 (or a total of 2 · 1011 free virions in the blood –
assuming 3 · 103ml of serum), since the coordinates of the equilibria of Section 3 represent the total
number of infected hepatocytes and of free virions, rescaled by dividing by H0 = 2 · 1011). It is
usually assumed that a percentage varying between 5% and 40% of the total number of hepatocytes
is productively infected in chronic HBV patients (see [8]). We take y1,1 = 0.25, whence p1 = 2.6.
c δ1 p1 v1,1 y1,1
0.65 0.0143 2.6 1 0.25
Table 2. Parameters from the literature.
We are still missing seven parameters: α1, α2, α3, p2, q2, q3, r3. We observe that different set of
parameters lead to different equilibria, in particular to different viral loads corresponding to v1,1,
v2,1, v3,1, v2,2, v3,2 and v3,3. Indeed these viral loads are functions of the parameters (see equations
in Section 3). With some algebraic effort, we can write six of the missing parameters as functions
of the six equilibrium viral loads and of the seventh parameter. Thus we derive expressions for α1,
α2, α3, p2, q2 and r3, depending on v1,1, v2,1, v3,1, v2,2, v3,2, v3,3 and q3. We choose q3 arbitrarily:
we assume that it is equal to 10−7 (it must be very small). Besides v1,1, which has been observed in
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the literature, the other viral loads are unknown. They depend on the strains involved, which are
by definition a priori unknown. Therefore we let the equilibrium viral loads vary among plausible
values. The choice of the plausible values is made according to some criteria:
(1) type 2 and type 3 have, at X1, negligible viral loads with respect to type 1, that is v1,1 
v2,1 ≥ v3,1;
(2) viral loads of a fixed type increase when the competitors are erased, that is, v3,3 > v3,2 >
v3,1, v2,2 > v2,1;
(3) we believe that the fact that type 1 has the largest fitness is also reflected by the fact that
when type 1 is removed from the system, the other two types can never exceed type 1’s
initial viral load, that is v1,1 ≥ vi,j for all i, j.
In principle, we let v2,1 and v3,1 vary from 9 to 4 orders of magnitude less than v1,1; v2,2 and v3,2
from 7 to 2 orders of magnitude less than v1,1; v3,3 from 7 to 1 order of magnitude less than v1,1.
As a second step, we compute the corresponding parameters α1, α2, α3, p2, q2 and r3. A set
of viral loads is possible only if the corresponding parameters have the correct biological meaning,
namely we require that
(1) all the parameters are positive;
(2) p1 ≥ q2 ≥ r3 (type 1 has a faster production rate, and type 2 is faster than type 3);
(3) p2/p1 and q3/q2 are small (error-free replications are less likely than mutations);
(4) at equilibria, the percentage of infected hepatocytes lies between 5% and 40%.
These requirements allow us to drop many of the plausible values. In Table 3 we write the range
of the viral loads v˜i,j (recall that v˜i,j = vi,j · (2 · 1011)/(3 · 103)). We let the loads vary from the
v˜2,1 v˜3,1 v˜2,2 v˜3,2 v˜3,3
min 6.7 6.7 · 10−2 6.7 · 102 6.7 · 103 6.7 · 102
max 6.7 · 102 6.7 6.7 · 105 6.7 · 106 6.7 · 106
Table 3. Range of equilibrium viral loads (in copies/ml).
minimum to the maximum, with a multiplicative step of 10 (thus, for instance the possibilities for
v˜2,1 are 6.7, 67 and 670). Among the 3
3 · 42 · 5 plausible cases from Table 3, only 46 satisfy all our
requirements. Moreover, for all these 46 parameter sets we got p2/p1 ≤ 10−5 and q3/q2 ≤ 10−3.
We performed stochastic simulations for all the 46 parameter sets (named “cases” hereafter).
The aim is to compare sequential monotherapy (drug A followed by drug B) with combination
therapy (drug A together with drug B), thus the efficacy parameters are needed. From [58] we have
ε(adefovir) = 0.993, while from [45] we have ε(lamivudine) ranging from 0.87 to 0.96 depending on
the dosage. In our numerical tests, we choose εA = 0.97 and εB1 = εB2 = 0.85: we assumed that
the first drug is highly efficient against the wild type, while the second drug, which acts also on
type 2, is less efficient. Although some papers assume that η is neither 0 nor 1 (see for instance
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[33, 40]), there are no explicit estimates of this parameter for the various drugs, hence we picked
ηA = ηB1 = ηB2 = 0.5 ([33] used as a plausible value 0.5).
As for the combination efficacies, we observe that combination therapy has a larger efficacy in
reducing the production rates (compared to single drug therapy); for instance [29] showed that,
at the dosage of their trial, lamivudine only has ε = 0.94, while combined with famciclovir it gets
ε = 0.988. Therefore it seems reasonable to rule out antagonism in combination therapy, and
consider only synergism, where εC ≥ max(εA, εB1) and ηC ≥ max(ηA, ηB1). The simplest way
to model synergism is to suppose that whenever a virus is the target of two drugs together, the
effects add in an independent manner. Namely, if drug A prevents a fraction ηA of virions of type
1 from infecting target hepatocytes, drug B will prevent a fraction ηB1 of the remaining virions
from infecting target hepatocytes, and the effect on replication will be analogous (just taking the
εs). In mathematical words, the combined efficacies of the cocktail drug A + drug B against
production of type 1 and against infection of new cells respectively, are εC = 1− (1− εA)(1− εB1)
and ηC = 1 − (1 − ηA)(1 − ηB1). If the patient is given drug A and drug B in combination, then
the viral load of type 1 decays more rapidly (R1 is multiplied by (1− ηC)(1− εC)) and the system
moves directly from X1 to X3.
4.2. Simulations. We simulated the course of the infection during a time lapse of 20 years (with
a six-hour step), monitoring the random time T when the viral load of type 3 exceeds 20 copies/ml
comparing therapy with only drug A, sequential monotherapy and combination therapy. In se-
quential therapy, drug B is prescribed when v˜2(t) > 667 cp/ml (recall that, according to [11], one
wishes to keep serum viral loads below 104 cp/ml). In all simulations, v˜1(0) = 0.67 · 108 cp/ml,
y1(0) = 0.25. The behaviour of the system highly depends on the initial values of v˜2(0) and v˜3(0).
In Table 4, T¯ is the average of the observed values of T among the 46 possible cases, in Table 4 the
cases were only 42 since in the remaining 4 the viral load of type 2 at equilibrium together with
the other strains was 6.7 cp/ml and therefore the system (which supposedly started some time in
the past with no mutants) cannot reach v˜2 = 67. Moreover, in the last column of Table 4, T¯ is the
average of T among the 6 cases where combination therapy did not eradicate the disease.
It appears that, if we want to delay the appearance of type 3 virions and we start therapy before
that third type mutations have taken place, then sequential monotherapy is slightly better than
monotherapy with drug A, but the advantage is small and is not even present in all cases. Indeed
the delay obtained with sequential therapy, with respect to monotherapy, ranges from -2% to 6% if
v˜2(0) = 6.7 cp/ml and from -1% to 5% if v˜2(0) = 67 cp/ml. On the other hand, in these situations
combination is strikingly better than sequential therapy. Combination therapy reaches the goal of
eradicating the disease in most cases and when it does not, the delay obtained, with respect to
monotherapy, ranges from 32% to 128%.
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only A sequential combination
T¯ = 5.17 years T¯ = 5.28 years disease always eradicated
Table 4. Comparison with v˜2(0) = 6.7 cp/ml and v˜3(0) = 0 cp/ml.
only A sequential combination healed combination
T¯ = 4.67 years T¯ = 4.76 years 36/42 cases T¯ = 7.84 years
Table 5. Comparison with v˜2(0) = 67 cp/ml and v˜3(0) = 0 cp/ml.
The advantage of combination therapy becomes less clear if simulations are started with v˜3(0) >
0. For instance if v˜3(0) = 1 cp/ml, then combination therapy was better than sequential therapy
only in 10 out of 46 cases and worse in 32 out of 46 cases (they were substantially equivalent in the
remaining 4 cases). It is not a priori clear how long it would take for a patient which is chronically
infected with the wild type virus, to develop mutating strains with a sufficiently high viral load to
make combination therapy a worse choice. We simulated chronic patients with no mutants which
start developing mutations but undergo no therapy whatsoever for 10 years and, starting from
the viral loads reached after these 10 years, we simulated other 10 years of therapy. The results
are stated in Table 4, where the two therapeutic approaches are considered equivalent if the delay
ranges in ±2%. It is important to note that there is complete healing in 11 of the 28 cases where
combination is preferable and even when sequential therapy is preferable the delay is at most 25%
of the corresponding time with combination therapy.
sequential combination seq. better comb. better equiv.
T¯ = 2.97 years T¯ = 3.90 years 13/46 28/46 5/46
Table 6. Comparison with v˜2(0) random.
v˜2(0) min delay when better max delay when better
7 always healing always healing
67 32% 128%
Random 2% 209%
Table 7. Delays with combination compared to sequential therapy.
Here are the plots of the viral load of type 3 in a case where combination therapy leads to healing.
The values of the parameters are c = 0.65, δ1 = δ2 = δ3 = 0.0143, p1 = 2.6, p2 = 3.6459 · 10−7,
q2 = 5.5182 · 10−4, q3 = 10−7, r3 = 5.7630 · 10−5, α1 = 4.7732 · 10−3, α2 = 19.3360, α3 = 181.7917.
Figure 4 has initial conditions v˜1(0) = 0.67 · 108 cp/ml, v˜2(0) = 67 cp/ml, v˜3(0) = 0. Figure 5
corresponds to the initial conditions v˜1(0) = 0.67 · 108 cp/ml, v˜2(0) = 67 cp/ml, v˜3(0) = 1 cp/ml.
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The plots of the viral loads of type 1 and 2 are not qualitatively different from the ones in Section 3.
Figure 4. Viral loads of type 3, under combination (left) or sequential therapy (right).
Figure 5. Viral loads of type 3, under combination (left) or sequential therapy (right).
5. Discussion
Drug resistance is a well-known cause of therapeutic failure. The simplest case where one can
test the ability of combination therapy (versus sequential monotherapy) to fight drug resistance, is
the case of a 3-strain infection with two drugs available (which act only against two variants of the
virus). The drug-resistant strains that will emerge under therapy are a priori unknown. This gives
the need of a general mathematical model for viral dynamics. The usual deterministic models do
not take into account stochastic fluctuations, which are not negligible when the viral loads of some
of the variants are low.
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In this paper we propose a stochastic model and simulate it with MatLab R2013b. We assume
that the reason why drug-resistant strains only appear during therapy is competition: the resistant
strains are less fit than the wild-type (together with the wild-type strain, even if present, mutants
remain numerically negligible). This assumption is considered the most likely explanation of drug
resistance, see [48]. We also believe that the drug-resistant variants emerge quite slowly, due to a
reduced speed of replication. The assumptions are reflected by some constraints on the infection,
production and mutation parameters of type 2 and type 3 strains. In order to run simulations we
need the numerical values of these parameters: the ones relative to the wild-type are taken from
the literature (Table 4). A mutation parameter (q3) is chosen arbitrarily, while the others are given
as functions of q3 and of the equilibrium viral loads that type 2 and type 3 can reach, with or
without therapy. Letting the equilibrium viral loads vary among plausible values (Table 3) we get
46 possible parameter sets (corresponding to 46 possible couples of type 2 and type 3 strains).
Our numerical analysis shows that combination therapy is by far the best choice if started at the
early stages of the chronic infection, while it seems that the advantage is not striking if therapy is
in act when drug-resistant mutants are already numerous and have started to significantly infect
the hepatocytes. This difference is not surprising, since if type 3 mutants are absent, they are
generated only by mutation from type 2, hence the need of lowering the number of type 2 virions
and infected cells. On the other hand, if type 3 mutants are already present, in some cases the
competition with other strains might slow the proliferation of the type 3 infection. In this model,
if drug-resistant strains are already present in abundance, the cure may open the way for their
proliferation. Nevertheless, we believe that in reality early therapy is always convenient, since
the probability that drug-resistant strains are already near equilibrium (together with the wild-
type) is very low, being these drug-resistant strains quite slow at reproduction. This is confirmed
by stochastic simulations run starting from a configuration with no mutants at the beginning:
in typical cases the mutants take years to reach equilibrium (which is another reason why drug-
resistant strains are seldom observed before therapy).
Moreover, we want to stress that our result are robust with respect to the arbitrary parameters.
Indeed we checked with simulations also q3 = 10
−6, ηA = 0.25, ηB = 0.25 (one change at a time)
and got the same qualitative results (what changed was the actual time of detection of type 3, not
which was the best therapy).
It is worth noting that, even if we were forced to make some arbitrary parameter choices and
the model is not fitted to any data (which is intrinsic in the problem itself since we want to
address unknown variants of the HBV), nevertheless the order of magnitude of the time before drug
resistance that we obtained is in accordance with the time observed in case trials. For instance in
[30, Table 1] many patients report, with different drugs, resistance after a treatment period ranging
from 3 to 6 years.
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The biological and clinical importance of this model is to show a clear advantage in favor of
the combination strategy, as it could lead to a greater delay in the development of drug-resistant
variants, which have less fitness than the wild type (drug sensitive) strain, but are able eventually
to escape from the therapy. The analysis of the model also puts emphasis on the need of an early
antiviral therapy.
By the way, there is also clinical evidence that the best choice is a broad spectrum early therapy:
for instance in [56] the authors observed that the emergence of entecavir-resistant strains is more
likely to appear in patients which were already lamivudine-resistant (rather than in treatment-naive
patients).
Another important point in favor of this regimen in the clinical practice is that the use of a
combination therapy could allow treating physicians to retrieve older and less expensive molecules
in developing countries, which truly are the settings where hepatitis B is most prevalent. In
addition, this approach could be a valid alternative in case of toxicity/intolerance to newer drugs,
such as for people with renal diseases unable to take tenofovir (which to date appears to be the
most promising drug in HBV therapy).
Concerning the type of combination therapy, ideally the best combination therapy for HBV
infection should consider the association between a high power drug and a high genetic barrier
drug. Power is the speed with which a drug causes the suppression of viral replication hence it is
proportional to the efficacy parameter ε introduced in Section 4). The genetic barrier represents
the number of mutations needed by the virus to replicate effectively in the presence of the therapy:
the higher is the genetic barrier of a drug, or of a combination regimen, the smaller set of mutants
are resistant to the treatment. Of course, nowadays entecavir or tenofovir are molecules which
are both powerful and show a low incidence of mutations. Indeed, after 4 years of treatment [30]
only 1.2% and 0% of the patients respectively, developed drug-resistance. Nevertheless, in principle
sooner or later drug-resistant mutants may appear with any drug, which is one argument in favour
of combination therapy even with these drugs at hand. Recent results show the appearance of drug
resistance in coinfected HBV-HIV patients, treated with tenofovir ([38]). The authors identify in
poor compliance to therapy the reason of this failure; it is our opinion that this is another aspect
to keep in mind.
In conclusion, we suggest to intervene in the natural history of HBV infection immediately and
with a broad-spectrum approach: a combination of powerful and high genetic barrier drugs. We
believe that combination therapy is less likely to select resistant strains, especially in patients with
a suboptimal compliance.
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